BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 17311304)

  • 1. Comparison of peripheral T-cell lymphomas and diffuse large B-cell lymphoma.
    Tomita N; Motomura S; Hyo R; Takasaki H; Takemura S; Taguchi J; Fujisawa S; Ogawa K; Ishigatsubo Y; Takeuchi K
    Cancer; 2007 Mar; 109(6):1146-51. PubMed ID: 17311304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi.
    Morabito F; Gallamini A; Stelitano C; Callea V; Guglielmi C; Neri S; Lazzaro A; Orsucci L; Ilariucci F; Sacchi S; Vitolo U; Federico M
    Cancer; 2004 Oct; 101(7):1601-8. PubMed ID: 15378507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of clinical outcome after autologous stem cell transplantation between patients with peripheral T-cell lymphomas and diffuse large B-cell lymphoma.
    Sohn BS; Park I; Kim EK; Yoon DH; Lee SS; Kang BW; Jang G; Choi YH; Kim C; Lee DH; Kim S; Huh J; Suh C
    Bone Marrow Transplant; 2009 Sep; 44(5):287-93. PubMed ID: 19234508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
    Oki Y; Yamamoto K; Kato H; Kuwatsuka Y; Taji H; Kagami Y; Morishima Y
    Eur J Haematol; 2008 Dec; 81(6):448-53. PubMed ID: 18691256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population.
    Yang S; Yu Y; Jun-Min L; Jian-Qing M; Qiu-Sheng C; Yu C; Wei-Li Z; Jian-Hua Y; Hui-Jin Z; Yan W; Li W; Shu C; Zhi-Xiang S
    Ann Hematol; 2009 Sep; 88(9):863-9. PubMed ID: 19205655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of bulky mass in the patient with primary extranodal diffuse large B cell lymphoma treated with R-CHOP therapy.
    Song MK; Chung JS; Sung-Yong O; Lee GW; Kim SG; Seol YM; Shin HJ; Choi YJ; Cho GJ; Shin DH; Yun EY
    Ann Hematol; 2010 Oct; 89(10):985-91. PubMed ID: 20428871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission.
    Papajik T; Raida L; Faber E; Vondrakova J; Prochazka V; Kubova Z; Skoumalova I; Jarosova M; M LK; Paucek B; Myslivecek M; Neoral C; Oral I; Jarkovsky J; Dusek L; Indrak K
    Neoplasma; 2008; 55(3):215-21. PubMed ID: 18348654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
    Natkunam Y; Farinha P; Hsi ED; Hans CP; Tibshirani R; Sehn LH; Connors JM; Gratzinger D; Rosado M; Zhao S; Pohlman B; Wongchaowart N; Bast M; Avigdor A; Schiby G; Nagler A; Byrne GE; Levy R; Gascoyne RD; Lossos IS
    J Clin Oncol; 2008 Jan; 26(3):447-54. PubMed ID: 18086797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical features and treatment outcomes of peripheral T-cell lymphoma, unspecified: a report of 78 cases].
    Yu YX; Shi YK; He XH; Zhou LQ; Zhou SY; Dong M; Feng FY; Sun Y
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(38):2714-6. PubMed ID: 18167252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffuse large B-cell lymphoma: clinical characterization and prognosis of Waldeyer ring versus lymph node presentation.
    Qi SN; Li YX; Wang H; Wang WH; Jin J; Song YW; Wang SL; Liu YP; Zhou LQ; Yu ZH
    Cancer; 2009 Nov; 115(21):4980-9. PubMed ID: 19634158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk-assessment in diffuse large cell lymphoma at first relapse. A study by the Italian Intergroup for Lymphomas.
    Guglielmi C; Martelli M; Federico M; Zinzani PL; Vitolo U; Bellesi G; Santini G; Tarella C; Zallio F; Pregno P; Di Renzo N; Resegotti L;
    Haematologica; 2001 Sep; 86(9):941-50. PubMed ID: 11532622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
    J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab.
    Gundrum JD; Mathiason MA; Moore DB; Go RS
    J Clin Oncol; 2009 Nov; 27(31):5227-32. PubMed ID: 19770371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
    Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
    Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical role of Bcl-2, Bax, or p53 overexpression in peripheral T-cell lymphomas.
    Jung JT; Kim DH; Kwak EK; Kim JG; Park TI; Sohn SK; Do YR; Kwon KY; Song HS; Park EH; Lee KB
    Ann Hematol; 2006 Sep; 85(9):575-81. PubMed ID: 16673127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma.
    Porrata LF; Ristow K; Habermann TM; Witzig TE; Inwards DJ; Markovic SN
    Am J Hematol; 2009 Feb; 84(2):93-7. PubMed ID: 19123458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas.
    Sonnen R; Schmidt WP; Müller-Hermelink HK; Schmitz N
    Br J Haematol; 2005 May; 129(3):366-72. PubMed ID: 15842660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
    Martín A; Conde E; Arnan M; Canales MA; Deben G; Sancho JM; Andreu R; Salar A; García-Sanchez P; Vázquez L; Nistal S; Requena MJ; Donato EM; González JA; León A; Ruiz C; Grande C; González-Barca E; Caballero MD;
    Haematologica; 2008 Dec; 93(12):1829-36. PubMed ID: 18945747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas.
    Niitsu N; Okamoto M; Nakamine H; Aoki S; Motomura S; Hirano M
    Hematol Oncol; 2008 Sep; 26(3):152-8. PubMed ID: 18395866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin.
    López-Guillermo A; Colomo L; Jiménez M; Bosch F; Villamor N; Arenillas L; Muntañola A; Montoto S; Giné E; Colomer D; Beà S; Campo E; Montserrat E
    J Clin Oncol; 2005 Apr; 23(12):2797-804. PubMed ID: 15728226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.